Locoregional therapy combined with systemic therapy (LRT + ST) for unresectable and metastatic intrahepatic cholangiocarcinoma: a systematic review and meta-analysis

Figures & Tables

Study	Country	Treatment			Sample		Age (years)		Sex (F:M)		Outcomes

		LRT + ST		ST	LRT + ST	ST	LRT + ST	ST	LRT + ST	ST
Yang, 2022²⁰	China	ADT: DEB-TACE (Doxorubicin)	ICIs (Camrelizumab or Sintilimab)	Gemcitabine + Cisplatin	20	20	59	59	9:11	7:13	OS, PFS, ORR, AEs
Yan, 2022²¹	China	Ablation: RFA / MWA	Gemcitabine^*	Gemcitabine^*	36	36	NR	NR	14:22	15:21	OS
Sun, 2021²²	China	ADT: TACI (5-Fluoruracil + cisplatin)	Gemcitabine + S-1	Gemcitabine + Cisplatin + S-1	33	33	NR	NR	NR	NR	OS, PFS, ORR, AEs
Gairing, 2021²³	Germany	ADT: TACE (Mitomycin C / Doxorubicin)	Gemcitabine^*	Gemcitabine^*	14	59	61.3	66.8	8:6	29:30	OS
Hu, 2020²⁴	China	ADT: DEB-TACE (Gemcitabine + Cisplatin) / cTACE (Gemcitabine + Cisplatin + lipiodol)	Apatinib	Apatinib	13	10	55.9	58.7	7:6	2:8	OS, PFS, ORR, AEs
Verma, 2018^25,&	America	EBRT	SYS	SYS	666	2176	65	65	309:357	1095:1081	OS
Chang, 2018^26,&	China	EBRT: CCRT / CTRT	Fluoropyrimidine^* / Gemcitabine^*	Fluoropyrimidine^* / Gemcitabine^*	211	211	60.11	60.80	81:130	84:127	OS
Konstantinidis, 2016²⁷	America	*ADT: HAI (Floxuridine^)**	Gemcitabine^* / Irinotecan^* / 5-Fluoruracil^*	Gemcitabine^* / 5-Fluoruracil^*	78	26	62	26	47:31	13:13	OS, ORR
Edeline, 2015^28,&	France	ADT: ⁹⁰Y SIRT	Gemcitabine^* / 5-Fluoruracil^*	Gemcitabine + Cisplatin^#	24	33	NR	NR	NR	NR	OS, PFS
Kim, 2013²⁹	Korea	EBRT: CCRT	Capecitabine + Cisplatin	Capecitabine + Cisplatin	25	67	56	58	6:19	14:53	OS, PFS, ORR, AEs